CN104800761B - 一种治疗产后抑郁症的中药组合物 - Google Patents
一种治疗产后抑郁症的中药组合物 Download PDFInfo
- Publication number
- CN104800761B CN104800761B CN201510218963.3A CN201510218963A CN104800761B CN 104800761 B CN104800761 B CN 104800761B CN 201510218963 A CN201510218963 A CN 201510218963A CN 104800761 B CN104800761 B CN 104800761B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- parched
- fructus
- taenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 201000009916 Postpartum depression Diseases 0.000 title claims abstract description 24
- 239000010271 massa medicata fermentata Substances 0.000 claims abstract description 16
- 241000628997 Flos Species 0.000 claims abstract description 15
- 241000244155 Taenia Species 0.000 claims abstract description 15
- 210000000582 semen Anatomy 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 241001597008 Nomeidae Species 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 235000010419 agar Nutrition 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims description 2
- 229910000020 calcium bicarbonate Inorganic materials 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 150000003376 silicon Chemical class 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 7
- 230000007774 longterm Effects 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 11
- 239000013641 positive control Substances 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 8
- 206010047700 Vomiting Diseases 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000008673 vomiting Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- 241000581650 Ivesia Species 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 238000012048 forced swim test Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229940023488 pill Drugs 0.000 description 3
- 238000001671 psychotherapy Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000004206 stomach function Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 235000015099 wheat brans Nutrition 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010011469 Crying Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000000571 coke Substances 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000921449 Rhodobryum roseum Species 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000010135 fructus aurantii immaturus Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000000051 music therapy Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000037047 psychomotor activity Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- -1 suspensoid Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组别 | 动物数 | 剂量 |
空白对照组 | 12 | 0.1ml/10g |
阳性对照组 | 12 | 5.0mg/kg |
本发明低剂量 | 12 | 0.5g/kg |
本发明中剂量 | 12 | 1.0g/kg |
本发明高剂量 | 12 | 2.0g/kg |
组别 | 病例数 | 痊愈(痊愈率) | 显著进步 | 进步 | 无效 | 总有效率 |
治疗组 | 110 | 70(63.6%) | 31 | 9 | 0 | 100.0% |
对照组 | 50 | 15(30.0%) | 14 | 10 | 11 | 78.0% |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510218963.3A CN104800761B (zh) | 2015-04-30 | 2015-04-30 | 一种治疗产后抑郁症的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510218963.3A CN104800761B (zh) | 2015-04-30 | 2015-04-30 | 一种治疗产后抑郁症的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104800761A CN104800761A (zh) | 2015-07-29 |
CN104800761B true CN104800761B (zh) | 2016-04-06 |
Family
ID=53686240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510218963.3A Expired - Fee Related CN104800761B (zh) | 2015-04-30 | 2015-04-30 | 一种治疗产后抑郁症的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104800761B (zh) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103536852A (zh) * | 2013-10-23 | 2014-01-29 | 罗田县精神卫生中心 | 一种治疗精神疾病的药物组合物及其用途 |
-
2015
- 2015-04-30 CN CN201510218963.3A patent/CN104800761B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN104800761A (zh) | 2015-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102048933B (zh) | 一种治疗小儿腹泻的中药组合物及其制备方法 | |
CN101361830A (zh) | 一种抗抑郁症的中药制剂及其制备方法 | |
CN101579119A (zh) | 一种具有润肠通便功能的营养食品及其制备方法 | |
CN102614407B (zh) | 一种治疗产后抑郁症的中药组合物 | |
CN105168935A (zh) | 通便美容的保健品及其制造方法 | |
CN103585479A (zh) | 用于治疗缺铁性贫血的补血丸和补血胶囊 | |
CN103585588A (zh) | 一种治疗小儿疳积病的中药组合物 | |
CN103735937A (zh) | 具有促进铁成分吸收并且补血的药物及保健品 | |
CN105106440B (zh) | 一种治疗腰麻后头痛头晕的中药组合物 | |
CN103705774A (zh) | 一种具有治疗抑郁症作用的复方组合物及其制备方法与应用 | |
CN104189819B (zh) | 一种用于调理情绪健康的中药制剂 | |
CN104623314A (zh) | 用于治疗口干口苦的药物组合物及其制备方法 | |
CN104800553B (zh) | 一种治疗更年期失眠症的中药组合物及其制备方法 | |
CN104800761B (zh) | 一种治疗产后抑郁症的中药组合物 | |
CN104383449B (zh) | 一种治疗郁病的药物组合物 | |
CN104689151A (zh) | 一种治疗糖尿病的中药组合物及其用途 | |
CN101129806A (zh) | 一种内服治疗抑郁症的中药组合物 | |
CN104688855B (zh) | 一种治疗慢性疲劳综合症的黄连阿胶组合物及其应用 | |
CN105232709A (zh) | 一种制备治疗产后抑郁症的中药组合物的方法 | |
CN105920447A (zh) | 一种抗抑郁的保健品及其制备方法 | |
CN105920409A (zh) | 一种用于治疗阿尔茨海默病的药物制剂及其用途 | |
CN104840764A (zh) | 一种治疗伤食型小儿急性腹泻的中药制剂及其制备方法 | |
CN105663577A (zh) | 一种产后护理的中药组合物及其制备方法 | |
CN105232708A (zh) | 一种治疗产后抑郁症的中药组合物 | |
CN104645244A (zh) | 一种治疗动脉硬化症的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Lu Na Inventor after: Guan Luanyou Inventor before: The inventor has waived the right to be mentioned |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160311 Address after: 402, room 1, building 2, building 119, 276000, ten Street, Lanshan District, Shandong, Linyi Applicant after: Lu Na Applicant after: Guan Luanyou Address before: 276017 Shandong Province, Luozhuang District Fu Zhuang Office after the village of coke, No. 5 Applicant before: Tang Guoping |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171204 Address after: Qidong City, Jiangsu province 226244 Nantong lvsigang Tianfen electric tools trade city comprehensive building Patentee after: Start the city of Fen Fen power tools technology innovation center Address before: 402, room 1, building 2, building 119, 276000, ten Street, Lanshan District, Shandong, Linyi Co-patentee before: Guan Luanyou Patentee before: Lu Na |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160406 Termination date: 20180430 |